Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Genome Med. 2011 Jul 27;3(7):49. doi: 10.1186/gm265.
A crucial limitation to our understanding of Alzheimer's disease (AD) is the inability to test hypotheses on live, patient-specific neurons. Patient autopsies are limited in supply and only reveal endpoints of disease. Rodent models harboring familial AD mutations lack important pathologies, and animal models have not been useful in modeling the sporadic form of AD because of complex genetics. The recent development of induced pluripotent stem cells (iPSCs) provides a method to create live, patient-specific models of disease and to investigate disease phenotypes in vitro. In this review, we discuss the genetics of AD patients and the potential for iPSCs to capture the genomes of these individuals and generate relevant cell types. Specifically, we examine recent insights into the genetic fidelity of iPSCs, advances in the area of neuronal differentiation, and the ability of iPSCs to model neurodegenerative diseases.
我们对阿尔茨海默病(AD)的认识存在一个关键的局限性,那就是无法在活体、患者特异性神经元上验证假说。患者尸检的样本供应有限,并且只能揭示疾病的终点。携带家族性 AD 突变的啮齿动物模型缺乏重要的病理,并且由于复杂的遗传学,动物模型在模拟散发性 AD 方面没有用处。诱导多能干细胞(iPSC)的最近发展为创建活体、患者特异性疾病模型和在体外研究疾病表型提供了一种方法。在这篇综述中,我们讨论了 AD 患者的遗传学以及 iPSC 捕获这些个体基因组并生成相关细胞类型的潜力。具体来说,我们研究了 iPSC 的遗传保真度、神经元分化领域的进展,以及 iPSC 模拟神经退行性疾病的能力等方面的最新进展。